Tenapanor Hydrochloride Patent Expiration

Tenapanor Hydrochloride is used for reducing serum phosphorus levels and treating hyperphosphatemia in adults. It was first introduced by Ardelyx Inc in its drug Ibsrela on Sep 12, 2019. Another drug containing Tenapanor Hydrochloride is Xphozah.


Tenapanor Hydrochloride Patents

Given below is the list of patents protecting Tenapanor Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Xphozah US10272079 NHE3-binding compounds and methods for inhibiting phosphate transport Apr 10, 2034 Ardelyx Inc
Xphozah US10940146 NHE3-binding compounds and methods for inhibiting phosphate transport Apr 10, 2034 Ardelyx Inc
Ibsrela US8541448 Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders Aug 01, 2033 Ardelyx Inc
Xphozah US8541448 Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders Aug 01, 2033 Ardelyx Inc
Ibsrela US9006281 Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders May 02, 2030 Ardelyx Inc
Ibsrela US12016856 Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders Dec 30, 2029 Ardelyx Inc
Ibsrela US8969377 Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders Dec 30, 2029 Ardelyx Inc
Ibsrela US9408840 Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorder Dec 30, 2029 Ardelyx Inc
Xphozah US12016856 Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders Dec 30, 2029 Ardelyx Inc
Xphozah US8969377 Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders Dec 30, 2029 Ardelyx Inc



A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Tenapanor Hydrochloride's patents.

Given below is the list recent legal activities going on the following patents of Tenapanor Hydrochloride.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 4th Yr, Small Entity 31 Oct, 2022 US10272079
Patent Issue Date Used in PTA Calculation 09 Mar, 2021 US10940146
Recordation of Patent Grant Mailed 09 Mar, 2021 US10940146
Email Notification 18 Feb, 2021 US10940146
Issue Notification Mailed 17 Feb, 2021 US10940146
Dispatch to FDC 10 Feb, 2021 US10940146
Email Notification 07 Jan, 2021 US10940146
Mail Response to 312 Amendment (PTO-271) 07 Jan, 2021 US10940146
Response to Amendment under Rule 312 04 Jan, 2021 US10940146
Application Is Considered Ready for Issue 31 Dec, 2020 US10940146


Tenapanor Hydrochloride's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List